Immatics Biotechnologies GmbH
- Country
- 🇩🇪Germany
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.immatics.com
Clinical Trials
30
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
- Conditions
- Recurrent CancerCancerRefractory CancerSolid Tumor, Adult
- Interventions
- Biological: IMA402 (Phase Ia)Biological: IMA402 (Phase Ib)Biological: IMA402 (Phase II)
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 145
- Registration Number
- NCT05958121
- Locations
- 🇩🇪
Universitaetsklinikum Heidelberg AöR, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪Universitaetsklinikum Mannheim GmbH, Mannheim, Baden-Wuerttemberg, Germany
🇩🇪Universitaetsklinikum Ulm AöR, Ulm, Baden-Wuerttemberg, Germany
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
- Conditions
- Recurrent CancerSolid Tumor, AdultRefractory CancerCancer
- Interventions
- Biological: IMA401 (Phase Ia)Biological: IMA 401 (Phase Ib)Biological: Pembrolizumab (Phase Ia)
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 95
- Registration Number
- NCT05359445
- Locations
- 🇩🇪
Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I, Freiburg, Baden-Wurttemberg, Germany
🇩🇪Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten, Heidelberg, Baden-Wurttemberg, Germany
🇩🇪Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie, Heidelberg, Baden-Wurttemberg, Germany
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
- Conditions
- Glioblastoma
- Interventions
- Drug: APVAC1 vaccine plus Poly-ICLC and GM-CSFDrug: APVAC2 vaccine plus Poly-ICLC and GM-CSF
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 16
- Registration Number
- NCT02149225
- Locations
- 🇩🇰
Rigshospitalet, The Finsen Centre, Department of Oncology, Copenhagen, Denmark
🇩🇪Neurologische Klinik & Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, Germany
🇩🇪Zentrum für Neurologie und Klinik für Neurochirurgie, Tübingen, Germany
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
- Conditions
- Glioblastoma
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT01403285
- Locations
- 🇺🇸
Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 339
- Registration Number
- NCT01265901
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Cedars-Siani Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Kaiser Permanente Oncology Hematology Clinic, Denver, Colorado, United States
- Prev
- 1
- 2
- Next